1 The EIC Accelerator Project

EIC Accelerator Program Overview

The EIC Accelerator is a prominent funding initiative under the European Innovation Council (EIC), aimed at supporting small and medium-sized enterprises (SMEs) and startups with high-risk, high-impact innovations in the European Union. This program provides blended finance, combining grants and equity investments, to help companies develop and scale their breakthrough technologies, particularly in the DeepTech sector.

Funding Structure

The EIC Accelerator offers significant financial support through a dual funding mechanism:

Purpose in the European Ecosystem

The EIC Accelerator serves a vital role in enhancing the European DeepTech ecosystem by nurturing startups and SMEs that are poised to tackle pressing societal challenges through technological advancements. By providing substantial funding, the program facilitates the transition from research and development to market entry, thereby fostering innovation, job creation, and global competitiveness.

The initiative takes a proactive approach to help companies scale their operations and attract further investment from the private sector. By de-risking early-stage investments, the EIC Accelerator encourages private investors to engage with high-potential startups, thus catalyzing a robust innovation ecosystem.

Case Study: Atamyo Therapeutics and the ATA-100 Project

Company Overview
Atamyo Therapeutics is a pioneering company based in France that specializes in developing advanced gene therapies for rare genetic disorders. The company has gained recognition for its innovative approaches to addressing complex medical conditions, particularly in the field of muscular dystrophies.

Project Overview
The EIC Accelerator project, designated as ATA-100, focuses on a smart, organotropic gene therapy designed specifically for the treatment of limb-girdle muscular dystrophy-R9 (LGMD-R9). This condition is characterized by progressive muscle weakness and degeneration, significantly impacting patients' quality of life.

Technology Background
ATA-100 leverages cutting-edge gene therapy techniques to deliver therapeutic genes directly to the target tissues, enhancing efficacy while minimizing potential side effects. The term "organotropic" refers to the technology's ability to preferentially target specific organs or tissues, thereby improving the precision of treatment. This focus on optimized efficacy also extends to considerations of patient safety and affordability, aiming to deliver a treatment that is not only effective but also accessible to patients who need it.

The technology is grounded in the principles of molecular biology and genetic engineering, utilizing viral vectors or other delivery mechanisms to introduce corrective genes into the affected muscle cells. By addressing the underlying genetic defect responsible for LGMD-R9, ATA-100 aims to halt or reverse the progression of the disease, providing a transformative solution for patients and their families.

Funding and Advancement
Atamyo Therapeutics submitted the Step 2 proposal for the EIC Accelerator on March 13, 2024, successfully advancing to the Step 3 interview stage, where they secured funding. The combination of grant and equity financing will enable Atamyo to expedite the development of ATA-100, conduct extensive clinical trials, and ultimately bring a groundbreaking therapy to market.

In summary, the EIC Accelerator plays a crucial role in supporting innovative companies like Atamyo Therapeutics, helping them navigate the complex landscape of biotechnology and gene therapy. Through significant funding and strategic guidance, the program fosters the development of technologies that can substantially improve patient outcomes in the realm of genetic disorders.

2 The Funding Rounds

Atamyo Therapeutics: Financing and Funding Overview Since EIC Accelerator Win

Atamyo Therapeutics, a French biotechnology company specializing in gene therapies for neuromuscular diseases, was among the winners of the EIC Accelerator March 2024 call. The following summarizes its financing history, funding rounds, investor information, valuations, and any exit-related developments since its successful application (submitted March 13th, 2024), with a focus on events from July 2024 onward.

Financing Raised & Funding Rounds

• In July 2024, Atamyo Therapeutics secured new financing through the European Innovation Council (EIC) Accelerator program.
• The company was awarded a grant totaling €2.5 million as part of this round.
• This funding was delivered under the blended finance scheme typical for EIC Accelerator awardees during this period—a combination of non-dilutive grants and potential equity investment.

Timing and Amounts

• Date Announced: July 15th, 2024
• Funding Type: Grant
• Amount: €2.5 million (approx. $2.7 million)
• This round represents Atamyo’s first publicized funding event in connection with the EIC Accelerator program during this timeframe.

Investor Information

• The main disclosed investor is the European Innovation Council via its highly competitive Accelerator scheme.
• For context: In this specific call cycle (March–July 2024), most selected companies received blended finance—grants combined with an equity component—though only grant allocation to Atamyo has been publicly confirmed so far.
• No other institutional or venture capital investors have been announced in relation to this particular round.

Further Financial Support

In September 2024, it was announced that The Dion Foundation for Children with Rare Diseases would finance Atamyo’s expansion into US clinical trials for ATA-200 gene therapy. While precise financial terms were not disclosed publicly regarding this partnership or sponsorship arrangement, it marks significant additional external support beyond EU-backed grants.

Earlier Public Financing

Prior to the EIC win: - In February 2022, Atamyo received non-dilutive public financing of €2 million from Bpifrance to support initiation of their first-in-man clinical trials for ATA‑100 therapy targeting LGMD2I/R9 . This is distinct from—but demonstrates a history of—public grant-based backing.

Company Valuation & Exit Events

• There are no available disclosures regarding company valuation or changes thereto as a result of these recent financings.
• No reports exist on secondary market transactions or valuation marks associated with venture rounds in connection with these events.
• There have been no IPOs (initial public offerings), buyouts/acquisitions by third parties (“exit events”), nor strategic M&A transactions reported involving Atamyo Therapuetics up through early May 2025.

Summary Table: Recent Key Financings

</em>Included for historical context

Additional Notes

Atamyo continues to develop novel gene therapies focusing on limb-girdle muscular dystrophies and has expanded regulatory clearances into Europe and preparations into US markets post-funding. Details about future venture capital involvement or equity tranches under “blended” arrangements may be forthcoming but have not yet been made public as per latest available sources.

Sources

• Atamyo Therapeutics Stock Price, Funding & Valuation – CB Insights
• Atamyo company information & funding – Impact Tech / Dealroom

• 200-gene-

  therapy-to-treat-limb-girdle-muscular-dystrophy-type-

  " class="inline-link" target="_blank" rel="noopener noreferrer">Press Release – Dion Foundation Partnership Expands US Clinical Trial

Atamy o Therapeutic

s Reaches Significant Regulatory and Financial Milestones – PDF Press Release

• 24-results-a-de tailed-analysis-of-funding-distribution-and-success-rates/ " class="inline-link" target="_blank" rel="noopener noreferrer"> E IC Accelera tor March 20

  24 Results Analysis — Rasph

  -[E IC Accelera tor Statistics — Strata.Team ] ( https:/ /www.strata.team/eic-acce lerator-statistics-and-results-from-the-march- 20

  24-call/

  )

  3 The Press Releases

  Atamyo Therapeutics, a French company, was among the winners of the European Innovation Council (EIC) Accelerator funding in March 2024. The company secured funding for its smart, organotropic gene therapy, ATA-100, designed for optimized efficacy, patient safety, and affordability. This innovative therapy aims to treat specific diseases by targeting organs effectively.

  Company Overview

  Atamyo Therapeutics focuses on developing gene therapies that can enhance treatment outcomes by ensuring targeted delivery and improved efficacy. Their approach involves leveraging advanced technologies to create more precise and safer treatments.

  Funding and Technology Advancements

  The EIC Accelerator funding supports Atamyo Therapeutics in advancing its gene therapy technology, ATA-100. This funding typically includes a combination of grants and equity investments, which are crucial for scaling up innovative projects like gene therapies. Blended finance, which combines grants and equity, was the preferred funding type for most winners in the March 2024 call, allowing companies to access both immediate capital and long-term investment opportunities.

  Partnerships and Updates

  There are no specific details available on new partnerships or team updates for Atamyo Therapeutics following the EIC Accelerator funding. However, such funding often facilitates collaborations and strategic partnerships that can further enhance the development and commercialization of innovative technologies.

  Press Releases and Updates on atamyo.com

  There is no available information on recent press releases or updates on Atamyo Therapeutics' website. Companies typically use their websites and social media platforms to announce significant developments, partnerships, or updates, but specific details for Atamyo Therapeutics are not currently available.

  ---

  Sources:

  • EIC Accelerator: Statistics and Results from the March 2024 call
  • Latest EIC Accelerator Results - Rasph
  • EIC Accelerator March 2024 Results: A Detailed Analysis of Funding Distribution and Success Rates
  • EIC Accelerator – 71 companies selected in the most competitive funding round so far

  4 The Technology Advancements

  Current Capabilities of Atamyo Therapeutics

  Atamyo Therapeutics, a clinical-stage biotechnology company based in France, specializes in developing new-generation gene therapies for musculoskeletal diseases, including limb-girdle muscular dystrophy (LGMD). The company's focus is on creating best-in-class gene therapies with enhanced safety and efficacy.

  Advancements Since EIC Accelerator Funding

  Following the specified date, Atamyo Therapeutics has made significant advancements in its gene therapy programs. Notably, the company received regulatory clearance to initiate clinical trials for its gene therapy candidate, ATA-200, in France and Italy. ATA-200 is designed to treat γ-sarcoglycan-related limb-girdle muscular dystrophy Type 2C/R5 (LGMD2C/R5), a severe form of muscular dystrophy primarily affecting children. The FDA also granted ATA-200 an Investigational New Drug (IND) clearance, allowing the expansion of its Phase 1b trial to the United States. This milestone marks ATA-200 as the first potential treatment for LGMD2C/R5 to enter clinical development in the U.S..

  Furthermore, Atamyo completed a dose-finding study for ATA-100, which targets fukutin-related protein (FKRP) limb-girdle muscular dystrophy Type 2I/R9 (LGMD2I/R9). ATA-100 is currently being evaluated in a multicenter Phase 1/2 clinical trial across Denmark and France.

  Technology Improvements and Demonstrations

  Atamyo has demonstrated its technology through ongoing clinical trials, showcasing the potential of its gene therapies. ATA-200 incorporates a new promoter that enhances liver and cardiac safety, reflecting advancements in gene therapy design. The trials for both ATA-200 and ATA-100 have been crucial in demonstrating the safety and potential efficacy of Atamyo's gene therapies in treating muscular dystrophies.

  New Features and Market Demonstrations

  The company's advancements highlight its commitment to improving gene therapy technology. ATA-200, in particular, has shown promise in preclinical models, correcting symptoms and disease biomarkers. The expansion of clinical trials to the U.S. further demonstrates Atamyo's ability to bring its technology to a broader market.

  Patents, Scientific Studies, and Clinical Trials

  Atamyo has been actively involved in advancing its gene therapies through clinical trials. However, specific details about new patents or published scientific studies are not readily available in the recent updates. The company's focus on clinical trials and regulatory approvals underscores its dedication to bringing innovative treatments to the market.

  Conclusion

  Atamyo Therapeutics continues to advance its gene therapy portfolio, with significant progress in clinical trials and regulatory approvals. The company's commitment to enhancing safety and efficacy in gene therapies positions it as a leader in treating muscular dystrophies.

  Sources

  • Atamyo | Gene Therapy for LGMD Patients
  • Atamyo completes the dose-finding study in Limb-Girdle Muscular ...
  • Atamyo Therapeutics' Gene Therapy ATA-200 Cleared for US Trial ...
  • Atamyo Therapeutics Obtains Regulatory Authorization in Europe to ...
  • Atamyo's Limb-Girdle Muscular Dystrophy Type 2C/R5 Gene Therapy Cleared for Clinical Trial in Italy and France
  • FDA OKs clinical trial of ATA-200 gene therapy for LGMD children
  • Atamyo obtains clearance for muscular dystrophy gene therapy trial
  • The Dion Foundation and Atamyo Therapeutics Announce a ...

  5 The Partnerships and Customers

  Atamyo Therapeutics: A French Biotechnology Company Advancing Gene Therapies

  Atamyo Therapeutics, a French clinical-stage biotechnology company, has been making significant strides in the field of gene therapies for muscular dystrophies and cardiomyopathies. Since receiving the EIC Accelerator funding in March 2024, Atamyo has been focusing on advancing its pipeline of innovative treatments.

  Partnerships and Collaborations

  One of the most notable partnerships for Atamyo Therapeutics is with The Dion Foundation for Children with Rare Diseases, based in the United States. This partnership announced in September 2024 aims to expand Atamyo's clinical trial of ATA-200, a gene therapy for treating Limb-Girdle Muscular Dystrophy Type 2C/R5 (LGMD2C/R5), into the US market. The Dion Foundation will finance the US portion of this trial, which has already received regulatory clearance in Europe.

  New Partnerships and Customers

  While specific new customers have not been detailed, the partnership with The Dion Foundation marks a significant step in Atamyo's expansion into the US market. This collaboration underscores the company's commitment to addressing rare genetic diseases globally.

  Nature and Purpose of New Relationships

  The partnership with The Dion Foundation primarily aims to facilitate the expansion of Atamyo's first-in-human trial of ATA-200 in the US. This strategic move is crucial for bringing groundbreaking gene therapies to patients with LGMD2C/R5, a condition caused by mutations in the γ-sarcoglycan gene.

  Market Positioning and Advancements

  By partnering with The Dion Foundation, Atamyo Therapeutics positions itself as a leader in the development of gene therapies for rare muscular dystrophies. This collaboration not only enhances Atamyo's market presence but also accelerates the development of potentially life-changing treatments. The support from The Dion Foundation will aid in scaling Atamyo's clinical trials and advancing its technological capabilities in gene therapy.

  The FDA clearance for ATA-200's Investigational New Drug (IND) application, combined with orphan drug designation, further reinforces Atamyo's commitment to innovation and patient care. This regulatory progress enables Atamyo to expand its trials globally, leveraging partnerships like the one with The Dion Foundation for successful technology advancements and market scaling.

  Future Prospects

  As Atamyo Therapeutics continues to build on its partnerships and technological advancements, it is poised to make a significant impact in the gene therapy sector. The company's ability to attract funding and collaborate with influential organizations like The Dion Foundation underscores its potential for growth and innovation.

  Sources

  • Atamyo
  • Press Releases
  • The Dion Foundation and Atamyo Therapeutics Announce a Partnership
  • Atamyo, Dion Foundation partner to expand LGMD study into US
  • Atamyo Therapeutics' Gene Therapy ATA-200 Cleared for US Trial

  6 The Hiring and Company Growth

  Atamyo Therapeutics: Team Growth and Development Following EIC Accelerator Funding While specific details about Atamyo Therapeutics' current hiring activities, headcount figures, or recent team expansions are not publicly disclosed in available sources, the company has demonstrated significant clinical and operational progress since early 2024. As a clinical-stage biotech focused on gene therapies for limb-girdle muscular dystrophies (LGMD), Atamyo’s growth is reflected in pipeline advancements rather than explicit team-size metrics.
  • Clinical Milestones Driving Operational Scaling:
  • ATA-100 for LGMD-R9: Completed dose-finding studies in April 2025, with plans to present detailed results later that year. The Rare Pediatric Disease Designation from the FDA underscores its potential to address unmet needs in pediatric populations.
  • ATA-200 for LGMD-R5: Cleared an IND by the FDA in November 2024 and secured regulatory authorization in Europe for clinical trials, indicating expanded R&D activities likely requiring specialized roles in regulatory affairs and clinical operations.
  • Leadership Stability: CEO Stephane Degove and CMO Sophie Olivier remain central figures, with no reported management changes since early 2024. Their expertise aligns with ongoing trials and partnerships, such as collaborations with The Dion Foundation to expand U.S. trials for ATA-200.
  • Strategic Hiring Implications: Though specific hires are not detailed, announcements of multicenter trials and conference participation (e.g., six events across the U.S. and Europe) suggest a need for roles like trial coordinators, data analysts, and business development professionals to support commercialization efforts.

  The absence of explicit headcount data highlights Atamyo’s focus on pipeline execution over public disclosures about staffing. However, their progression into pivotal trial phases implies targeted hiring to manage increased operational complexity ahead of potential regulatory submissions.

  ---

  Sources

  • Atamyo completes dose-finding study
  • IND clearance for ATA-200
  The Dion Foundation partnership announcement via ZoomInfo

  7 The Media Features and Publications

  Atamyo Therapeutics: A Leading Biotech Company in France

  Atamyo Therapeutics, based in France, has gained significant attention in the biotech industry, particularly following its success in securing funding from the EIC Accelerator in March 2024. Here is an overview of the company's media features, publications, and events participation:

  Media Features and Publications

  Atamyo Therapeutics has been featured in several publications for its innovative gene therapy approaches. In March 2024, the company received regulatory clearance to initiate a Phase Ib trial for ATA-200, targeting limb-girdle muscular dystrophy Type 2C/R5, marking a significant milestone in the field of neuromuscular diseases. Additionally, Atamyo has been noted for its participation in the EIC Accelerator funding round, receiving a grant of €2.5 million to support its research and development efforts.

  Content from Publications

  Publications have highlighted Atamyo's focus on developing new-generation gene therapies for muscular dystrophies. The company's mission is to bring best-in-class treatments to patients suffering from neuromuscular diseases, with a current pipeline that includes treatments for various types of limb-girdle muscular dystrophies (LGMDs).

  Podcasts or Interviews

  While specific podcast interviews are not readily available, Atamyo's CEO, Stéphane Degove, and other executives have provided corporate overviews and updates on the company's pipeline progress at several conferences in the US and Europe.

  Conference and Fair Visits

  Atamyo Therapeutics has actively participated in numerous conferences to showcase its research and development progress:

  • Sach's 20th Annual Biotech in Europe Forum in Basel, Switzerland
  • Chardan’s 8th Annual Genetic Medicines Conference in New York City
  • The Cell & Gene Meeting on the Mesa in Phoenix
  • Additional scientific conferences in the US and Europe to present updates on LGMD clinical development programs.

  Involvement in Events

  Atamyo's involvement in these events highlights its commitment to advancing gene therapy for neuromuscular diseases and engaging with the global biotech community.

  Sources:

  • Atamyo Therapeutics Stock Price, Funding, Valuation, Revenue
  • Atamyo obtains clearance for muscular dystrophy gene therapy trial
  • Atamyo
  • Atamyo company information, funding & investors
  • Atamyo Therapeutics to Provide Corporate Overviews and Updates